An evaluation of the SENTiFIT 270 analyser for quantitation of faecal haemoglobin in the investigation of patients with suspected colorectal cancer. by Augé Fradera, Josep Maria et al.
Clin Chem Lab Med 2018; 56(4): 625–633
Josep M. Auge*, Cristina Rodriguez, Oihana Espanyol, Liseth Rivero, Silvia Sandalinas, Jaume 
Grau, Wladimiro Jimenez and Antoni Castells
An evaluation of the SENTiFIT 270 analyser for quantitation 
of faecal haemoglobin in the investigation of patients with 
suspected colorectal cancer
https://doi.org/10.1515/cclm-2017-0605
Received July 11, 2017; accepted October 9, 2017; previously published 
online November 18, 2017
Abstract
Background: An evaluation of SENTiFIT® 270 (Sentinel 
Diagnostics, Italy; Sysmex, Spain) analyser for the quanti-
tation of faecal haemoglobin (f-Hb) was performed.
Methods: The analytical imprecision, linearity, carry over 
and f-Hb stability were determined. Evaluation of the 
diagnostic accuracy was performed on 487 patients.
Results: Within-run and between-run imprecision ranged 
1.7%–5.1% and 3.8%–6.2%, respectively. Linearity studies 
revealed a mean recovery of 101.1% (standard deviation, 
6.7%) for all dilutions. No carry over was detected below 
7650 μg Hb/g faeces. Decay of f-Hb in refrigerated samples 
ranged 0.2%–0.5% per day. f-Hb in patients with advanced 
colorectal neoplasia (ACRN) (colorectal cancer [CRC] plus 
advanced adenoma [AA]) were significantly higher than 
from those with a normal colonoscopy. Sensitivity for 
ACRN at f-Hb cutoffs from 10 to 60 μg Hb/g faeces ranged 
from 28.9% (95% confidence interval [CI], 21.7%–37.2%) to 
46.5% (95% CI, 38.1%–55%), the specificity ranged from 
85% (95% CI, 82.3%–87.3%) to 93.2% (95% CI, 91.2%–
94.8%), positive predictive values for detecting CRC and 
AA ranged from 11.6% (95% CI, 7.6%–17.2%) to 20.6% (95% 
CI, 13.3%–30.3%) and from 34.7% (95% CI, 28.1%–42%) to 
42.3% (95% CI, 32.4%–52.7%), respectively, and the nega-
tive predictive value for ACRN ranged from 90.2% (95% 
CI, 87.9%–92.2%) to 88.4% (95% CI, 86%–90.4%). Using 
two samples per patient sensitivity increased with a slight 
decrease in specificity.
Conclusions: The analytical and clinical performances of 
SENTiFIT assay demonstrate a specific and accurate test 
for detecting ACRN in symptomatic patients and those 
undergoing surveillance.
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Introduction
The faecal immunochemical test (FIT) for faecal haemo-
globin (f-Hb) has been widely adopted in screening pro-
grammes [1–4], and its usefulness for assessing patients 
with lower gastrointestinal symptoms has begun to be 
explored [5–11].
The FIT allows for quantitative measurement of f-Hb 
concentration, which makes it possible to select the 
optimal cutoff [2, 12–16] for each situation. Quantitative 
FIT generally uses automated analysis to determine f-Hb 
concentration, which allows high-throughput testing, 
improves reproducibility, and removes bias in the inter-
pretation of the results [17].
In the last few years, the number of analysers, rea-
gents and specimen collection devices available on the 
market has increased. Currently, several FIT manufac-
turers offer analytical systems that differ in terms of, for 
instance, the volume of haemoglobin-stabilising buffer 
in the specimen collection devices and the sample mass 
used for the test [18]. Initiatives to standardise methods 
and reporting units have been undertaken [19–22]. Nev-
ertheless, each brand of FIT performs differently [23]. For 
this reason, it is advisable to evaluate the features of FIT 
reagents, analysers and specimen collection devices prior 
to use.
The main aim of this study was to assess the analyti-
cal and diagnostic capabilities of SENTiFIT® 270 using 
SENTiFIT®–FOB Gold® latex reagent and SENTiFIT® 
pierceTube (Sentinel Diagnostics, Italy; Sysmex, Spain). 
As a secondary aim, we studied the diagnostic yield for 
advanced colorectal neoplasia (ACRN) of f-Hb concentra-
tion using the first result of two samples vs. the mean and 
the higher concentration of two samples.
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Materials and methods
Patients
The study analysed 487 consecutive patients (48.8% males) whose 
average age was 62  years (range: 22–94  years), who attended the 
 Hospital Clinic of Barcelona from June to October 2015 for colonos-
copy to assess lower gastrointestinal symptoms (264 patients) or for 
surveillance of colonic polyps (223 patients).
Patients were asked to begin collecting faecal samples for the 
FIT 5 days before their colonoscopy to ensure that two samples were 
collected before bowel preparation commenced. No dietary restric-
tions were imposed. Medication such as aspirin and non-steroidal 
anti-inflammatory drugs was discontinued 1  week before prepara-
tion for colonoscopy. The study was approved by the Hospital Clinic’s 
Ethics Committee (HCB/2015/0388), and all patients provided writ-
ten informed consent. All participants received an explanation of the 
tests and written instructions for the FIT either face to face or over 
the telephone. Patients were asked to prepare faecal samples from 
two consecutive bowel motions using the collection kit provided by 
the manufacturer.
Samples
Three sample sources were used: (1) samples collected by the 
patients, (2) stabilising buffer spiked with human capillary blood 
and (3) control material provided by the manufacturer. To collect a 
sample, the patient unscrews the green cap with the attached sam-
ple collection stick and inserts it in four different spots in the faeces, 
scratching the surface cross-wise. The grooves of the stick must be 
fully covered in faeces. Then, the patient replaces the stick into the 
specimen collection device and screws it shut. The collection device 
is designed to collect 10 mg of freshly passed faeces with a serrated 
stick in a standard volume of haemoglobin-stabilising buffer (1.7 mL). 
Samples were stored in double-zipper bags at 4 °C until analysis was 
performed (within a maximum of 5 days).
Analyser
SENTiFIT® 270 was used for quantitation of the f-Hb (Sentinel Diag-
nostics, distributed in Spain by Sysmex España, S.L.U.). This is a desk-
top instrument based on immunoturbidimetry that can perform up to 
270 tests per hour. It includes SENTiFIT® FOB Gold® latex reagent, 
FOB Gold® Screen Diluent, washing and fluid-disposal bottles, and it 
requires access to a standard power supply. Forty faecal samples pre-
pared by patients using the SENTiFIT® pierceTube were loaded into 
the sample carousel. The instrument automatically mixes the faecal 
buffer solution with a latex-antihuman haemoglobin antibody rea-
gent. The latex particles react with faeces samples containing human 
haemoglobin. The agglutination of the latex particles is proportional 
to the concentration of haemoglobin in the sample. By applying a 
conversion factor of 0.17, the concentration of haemoglobin in the 
buffer (ng Hb/mL buffer) can be used to determine the concentration 
of haemoglobin in faeces (μg Hb/g faeces). The measurement range 
is from 2 to 129 μg Hb/g faeces, the highest calibration concentra-
tion. All events were performed in accordance with the maintenance 
tasks, calibration methods and quality controls recommended by 
the manufacturer. The analyses were performed by a trained clini-
cal laboratory technician. The laboratory has a total quality manage-
ment system and is certified to ISO 9001:2015 standards by AENOR, 
Asociación Española de Normalización y Certificación (Spain).
Protocol design
An evaluation protocol was designed that included a training period 
and an analytical evaluation phase in which imprecision, the lin-
earity of dilution, the carry over and f-Hb stability were examined. 
A clinical evaluation was performed to compare the f-Hb concentra-
tions for different colonoscopy findings, including receiver operating 
characteristic (ROC) curves. Adenomas measuring 10 mm or more in 
diameter with villous architecture, high-grade dysplasia or intramu-
cosal carcinoma were classified as advanced adenoma (AA). Invasive 
colorectal cancer (CRC) was considered to be present when malig-
nant cells were observed beyond the muscularis mucosae. ACRN 
was defined as AA or invasive CRC. The sensitivity and specificity for 
CRC, AA and ACRN at different f-Hb cutoffs using all collected sam-
ples were assessed as well as the diagnostic yield at different cutoffs, 
achieved using the first f-Hb concentration of two samples and the 
mean and the higher f-Hb concentration of two samples.
Analytical imprecision: Six samples (two controls, two haemoglo-
bin-spiked buffers and two f-Hb patient samples) were quantified 
and repeatedly examined 19 times in 1 day, and two controls were 
examined every day for at least 20  days. The mean, the standard 
deviation (SD) and the coefficient of variation (CV) of each sample 
were calculated.
Linearity: The highest concentration standard (129 μg Hb/g faeces) 
was diluted with the appropriate buffer diluent to obtain a minimum 
of five dilutions within the dynamic range of the assay. Dilutions were 
prepared using calibrated pipettes. Recovery was calculated accord-
ing to the highest measured concentration.
Sample carry over: carry over was determined using two human 
blood-spiked buffer samples: a sample with a low test result close to 
the relevant decision cutoff (~20 μg Hb/g faeces) and a sample with 
a very high haemoglobin concentration (7650 μg Hb/g faeces). The 
samples were divided into 10 low aliquots (L) and 5 high aliquots (H). 
The aliquots were loaded into the analyser in the following order: L, 
L, L, L, L, H, L, H, L, H, L, H, L, H, L. The difference between the mean 
of the low measurements after a high measurement and the mean of 
the low measurements after a low measurement is equal to the carry-
over. The maximum deviation was defined as twice the SD of the first 
five low measurements [24].
Test stability: Thirteen of the patients’ samples ranging from 12 
to 1001 μg Hb/g faeces were aliquoted into single-use Eppendorf 
tubes to avoid contamination. They were stored at room temperature 
and then refrigerated and periodically analysed over 20 days. Their 
cumulative change compared with the initial measurement was 
reported as a ratio.
Endoscopy: Colonoscopies were performed without knowledge of 
the FIT results, and only those reaching the caecum or an obstructing 
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carcinoma, if present, were selected. All lesions were categorised, 
and if colorectal polyps were detected, the polyp sites were recorded 
and polypectomy was performed. Polyps were examined histologi-
cally, and the size and type of each polyp were recorded according 
to the guidelines published by the European Society of Gastrointes-
tinal Endoscopy [25]. The location and histology of carcinomas were 
also recorded. Polyps were categorised as either AA or non-advanced 
adenoma (NAA). Tumour staging was performed according to the 
TNM classification system used by the Union for International Can-
cer Control (UICC) [26]. Patients were classified according to the most 
advanced lesion present.
Statistical analysis
A logarithmic transformation was performed to obtain a graphic rep-
resentation of f-Hb concentrations. The Mann-Whitney U-test was 
used to analyse differences between groups’ haemoglobin concen-
trations. An ROC curve for the FIT was drawn to determine the f-Hb 
cutoffs. Sensitivity, specificity and their 95% confidence interval (CI) 
were determined with the following two equations:








The positive predictive value (PPV), negative predictive value 
(NPV) and their 95% CI for ACRN, CRC and AA at different f-Hb con-
centrations were also calculated. The ROC curves for one and two 
tests were compared using the Delong method, and differences in 
sensitivity and specificity were calculated using one and two samples 
at the same cutoff. We determined the Pearson correlation coefficients 
of each pair of measurements. Cohen’s κ coefficient was calculated to 
measure the agreement between the first and the second FIT. Statisti-
cal analysis was performed using PASW Statistics 18, Release Version 
18.0.0 (SPSS, Inc., 2009, Chicago, IL, USA) and GraphPad Prism Ver-




The within-run imprecision CVs of the low control 
(mean ± SD) (14 ± 1 μg Hb/g faeces), high control 
(49 ± 1  μg Hb/g faeces), haemoglobin-spiked buffers 
(29 ± 2 μg Hb/g faeces; 96 ± 4 μg Hb/g faeces) and f-Hb 
patient samples (18 ± 1 μg Hb/g faeces; 100 ± 3 μg Hb/g 
faeces) ranged from 1.7% to 5.1%. Between-run impreci-
sion CVs of the low control (mean ± SD) (14 ± 1 μg Hb/g 
faeces) and high control (51 ± 2 μg Hb/g faeces) ranged 
from 3.8% to 6.2%.
Linearity
Mean linearity was 101.1% for all dilutions (minimum 
84.5%, maximum 108.1%), with an SD of 6.7% (Figure 1).
Carry over
The means and SDs of f-Hb concentrations after low and 
high concentration samples (7650 μg Hb/g faeces) were 
22 ± 2 μg Hb/g faeces and 23 ± 1 μg Hb/g faeces, respec-
tively. The maximum deviation was defined as twice the 
SD of the first five low measurements; therefore, the intra-
assay carry over met the requirements.
Test stability
The decay of concentration (mean ± SD) that occurred 
each day the samples were stored at room temperature 
(24 °C ± 2 °C) was significantly higher than when they were 
refrigerated (6 °C ± 2 °C) (p < 0.05). The decay per day, over 
20  days, at room temperature ranged from 1.4% to 11% 
(2.3% ± 1.2%) and when refrigerated ranged from 0.2% to 
0.5% (0.4% ± 0.3%) per day.
Clinical performance
Patient and colonoscopy results
Of the 487 patients, 71  showed ACRN on colonoscopy 






























Expected concentration, µg Hb/g faeces
y = 1.024x – 0.359
R2 = 0.996
Figure 1: Linear regression of expected and observed dilution steps.
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(19.1%), and other lesions, such as hyperplastic or inflam-
matory polyps (28), diverticular disease (114), haemor-
rhoids (149), angiodysplasia (7), inflammatory bowel 
disease (8) and minor irrelevant lesions (6), were found 
alone or in combination in 230 patients (47.2%). Finally, 
there were no colonoscopy findings for 93 individuals 
(19.1%).
f-Hb concentrations
For the entire population undergoing colonoscopy, 
the median and interquartile range (IQR) of the f-Hb 
 measurements for each of the analysed samples were 
2 and 2–5 μg Hb/g faeces, respectively. The f-Hb results 
according to colonoscopy and pathology diagnosis are 
presented in Table 1. The f-Hb concentrations for patients 
with ACRN (CRC + AA) were significantly higher than 
those with a normal colonoscopy examination (Figure 2). 
The results above 10, 20, 40 and 60 μg Hb/g faeces were 
19.6%, 15.8%, 11.5% and 10%, respectively.
Sensitivity, specificity and predictive values for different 
colonoscopy findings, including ACRN
Figure 3 shows the ROC curve for CRC and ACRN based on 
the FIT results for each participant. We measured the sen-
sitivity and specificity of the FIT results at various haemo-
globin cutoffs (Table 2). At a 10 μg Hb/g faeces cutoff, the 
sensitivity and specificity for detecting ACRN were 46.5% 
(95% CI, 38.1%–55%) and 85% (95% CI, 82.3%–87.3%), 
respectively. At 30 μg Hb/g faeces cutoff, the sensitivity 
and specificity for detecting ACRN were 33.8% (95% CI, 
26.2%–42.3%) and 91% (95% CI, 88.8%–92.8%), respec-
tively. When a 10 μg Hb/g faeces cutoff was used, sensi-
tivity increased by 35% and specificity decreased by 7% 
compared with a 30 μg Hb/g faeces cutoff. The sensitivity 
for detecting CRC was considerably higher than that for 
detecting clinical ACRN (Table 2). In the studied group, the 
PPV for detecting CRC and ACRN at cutoffs between 10 and 
60 μg Hb/g faeces ranged from 11.6% to 20.6% and from 
34.7% to 42.3%, respectively, and the NPV for ACRN ranged 
from 90.2% to 88.4%. Table 2 also includes the sensitivity 
and specificity of FIT at various f-Hb cutoffs for different 
colonoscopy findings. In the studied group, the sensitivity 
for detecting all types of colorectal lesions between cutoffs 
of 10 and 60 μg Hb/g faeces ranged from 11.9% to 23% and 
the specificity ranged from 94.6% to 97.8%.
Diagnostic yield using one or two samples
The correlation coefficients of the first and the second 
FITs were 0.46. The κ coefficient at different cutoff values 
(Table 3) showed a substantial agreement between the 
first and the second FITs. We measured f-Hb of each of two 
consecutive faecal samples but considered them to repre-
sent one test, to which we assigned the mean and higher 
result of the two FITs. Figure 4 shows the ROC curves for 
ACRN based on the first, mean and higher FIT measure-
ments for each participant. No statistical differences were 
observed among these measurements. Table 3 shows the 
sensitivity and specificity of the first, second, higher and 
mean FIT results for ACRN at different cutoff values, as 
well as discrepancies between the first and the second 
sample and the κ coefficient between both samples.
Table 1: μg Hb/g faeces concentration of all samples according to 
colonoscopy and pathology diagnosis.
Diagnosis No. of samples Median IQR p-Valuea
CRC 24 637 101–1034 <0.001
CRC + AA 142 8 2–93 <0.001
Adenomas
AA 118 3 2–25 <0.001
NAA 183 2 2–11 <0.001
Other 456 2 2–4 0.002
Normal 186 2 2–2
CRC, colorectal cancer; AA, advanced adenoma; NAA, non-advanced 
adenoma; IQR, interquartile range. Concentrations ≤ 2 μg Hb/g 
faeces might be below the limit of detection. aSignificance in 


















Figure 2: Box plot of f-Hb concentration according to colonoscopy 
and pathology diagnosis.
CRC, colorectal cancer; AA, advanced adenoma; NAA, non-advanced 
adenoma; LLQ, lower limit of quantification.
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Discussion
To our knowledge, this is the first study to report detailed 
analytical and clinical data using the SENTiFIT® 270 ana-
lyser (Sentinel Diagnostics, distributed in Spain by Sysmex 
España, S.L.U.). This colonoscopy-controlled study per-
mitted a detailed evaluation of an automated desktop 
instrument for quantitative immunochemical determina-
tion of f-Hb. The evaluation included studies of impreci-
sion, linearity of dilution, carry over and test stability as 
well as a clinical study to assess the diagnostic yield.
The analytical imprecision was below 6.2%. Further-
more, the effects of carry over were not detected below 
7650 μg Hb/g faeces. In a hypothetical situation in which 
a sample with a haemoglobin concentration higher than 
7650 μg Hb/g faeces was followed by a sample with a 
haemoglobin concentration near the decision cutoff, 
reanalysis of the latter sample would need to be consid-
ered to avoid haemoglobin contamination. However, this 
situation is very rare (0.4% of the samples of the present 
study) because few samples have such high f-Hb and even 
fewer are followed by a sample near the decision cutoff. 
Haemoglobin stability was evaluated at different tem-
peratures. Samples stored in a refrigerated environment 
showed slight decay (0.2%–0.5% per day) compared with 
those stored at room temperature (1.4%–11% per day).
In a mixed group of individuals, the sensitivity and 
specificity for ACRN at cutoffs between 10 and 60 μg Hb/g 
faeces ranged from 28.9% (95% CI, 21.7%–37.2%) to 46.5% 
(95% CI, 38.1%–55%) and from 85% (95% CI, 82.3%–
87.3%) to 93.2% (95% CI, 91.2%–94.8%), respectively. It is 
important to note that the high specificity and NPV (90%) 
helps rule out the presence of ACRN, which is a relevant 
issue in symptomatic patients. The specificity of all types 
of colorectal lesions at cutoffs between 10 and 60 μg Hb/g 
faeces is very high (94.6%–97.8%), as is the PPV for detect-
ing colorectal lesions (95.9%–94.7%). However, sensitiv-
ity and NPV for all detected lesions are very low, ranging 
from 11.9% to 23% and from 20.9% to 22.7%, respectively. 
This ensures detection of colorectal pathology but does 
not rule out minor findings such as NAA or other minor 
lesions. It is important because when f-Hb is below an 
established cutoff, severe lesions can be ruled out and 
only some minor lesions may be overlooked.
Due to the study’s characteristics, all patients were 
symptomatic or under surveillance, and therefore the 
positivity rate at different cutoffs was higher than in aver-
age-risk populations [27, 28]. Thus, further studies are 
necessary. The poor correlation between the first and the 
second samples can probably be ascribed to the reproduc-
tion of daily variations in blood loss, heterogeneous blood 
distribution inside faeces and the inherent characteristics 
of the specimen collection devices. Otherwise, the κ coef-
ficients and the discrepancies between the first and the 
second FITs at different cutoff values showed a substantial 
agreement and a proportion of discrepancies below 7%.
This study confirmed that using a 40 μg Hb/g faeces 

































Figure 3: Receiver operating characteristic (ROC) curve of f-Hb 
concentration from all samples for the identification of CRC (A) and 
ACRN (B).
ACRN, advanced colorectal neoplasia; CRC, colorectal cancer; AUC 
(95% CI), area under the curve (95% CI).
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21.2% of AAs, resulting in a combined sensitivity of 31.7% 
and a specificity of 92%. By using two samples for each 
patient and choosing the highest result, the sensitiv-
ity for ACRN increases to 40%, resulting in a specificity 
of 88.6%, while on the other hand a similar diagnostic 
yield is obtained using only one sample and decreasing 
the cutoff. Moreover, when one sample and a 10 μg Hb/g 
faeces cutoff are used, it is possible to rule out the majority 
of malignant lesions, missing two CRCs out of 24, obtain-
ing a very high NPV (99.7%), a characteristic observed for 
all f-Hb concentrations and even at a 60 μg Hb/g faeces 
cutoff, missing four CRCs out of 24, maintaining a high 
NPV (99.5%). These results can help make decisions not 
only related to the performance and prioritisation of colo-
noscopies for symptomatic patients but even ruling out 
malignancy in patients with low f-Hb concentrations. 
Additionally, they are consistent with results from a 
screening set and other studies that used immunochemi-
cal tests to screen larger populations [5, 6, 29–35].
Conclusions
In conclusion, the current study provides useful data 
regarding the potential application of an automated FIT to 
CRC screening and diagnosis of symptomatic patients. The 
compact, fully automated immunochemistry analyser, 
which evaluated f-Hb demonstrated adequate analytical 
and clinical performance. The test used in the current 
study is easy to perform, and the results are independent 
of the operator’s experience. We have demonstrated that 
the SENTiFIT assay (Sentinel Diagnostics, Italy; Sysmex, 
Spain) is a specific and accurate test for detecting ACRN in 
symptomatic patients and those undergoing surveillance.
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